Daratumumab,Talquetamab,Teclistamab,Pomalidomide
janssen,genmab
['cart,(-cartitude)', 'daratumumab', 'talquetamab']
talquetamab sc combined with daratumumab sc across two doses with weekly/q2 weekly dosing schedules, shows a response rate 76.5%, mrd- 27% at 10-5 via ngs, crs ~65% (grade 1/2), dysgeusia 57%, median follow-up 4 months #cartsm #mediq22asco #eha2022
Chief of Myeloma @MSKCancerCenter | Chair @ALLIANCE_org #mmsm Comm. |Physician ? Provider| @ASH_hematology @ASTCT @ASCO |married to @ZainabShd | #BMTsm #CARTsm